Literature DB >> 23194039

Worldwide overview of the current status of lung cancer diagnosis and treatment.

Paul A Bunn1.   

Abstract

Lung cancer is the leading worldwide cause of cancer deaths. Smoking is the dominant cause of lung cancer and smoking cessation is the established method to reduce lung cancer mortality. While lung cancer risk is reduced in former smokers, they have a lifelong increase in risk, compared to never-smokers. Novel chemoprevention strategies, such as oral or inhaled prostacyclin analogs, hold promise for these subjects. Low-dose spiral computed tomography screening reduced lung cancer mortality by 20% in high-risk heavy smokers older than 50 years. However, the high false-positive rate (96%) means that screened patients required controlled follow-up in experienced centers. An increasing percentage of patients with advanced lung cancer have molecular drivers in genes for which oral tyrosine kinase inhibitors have been developed.

Entities:  

Mesh:

Year:  2012        PMID: 23194039     DOI: 10.5858/arpa.2012-0295-SA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  28 in total

1.  A reevaluation of CD22 expression in human lung cancer.

Authors:  Laurentiu M Pop; Stephen Barman; Chunli Shao; Jonathan C Poe; Guglielmo M Venturi; John M Shelton; Iliodora V Pop; David E Gerber; Luc Girard; Xiao-yun Liu; Carmen Behrens; Jaime Rodriguez-Canales; Hui Liu; Ignacio I Wistuba; James A Richardson; John D Minna; Thomas F Tedder; Ellen S Vitetta
Journal:  Cancer Res       Date:  2014-01-01       Impact factor: 12.701

Review 2.  Dietary agents for prevention and treatment of lung cancer.

Authors:  Naghma Khan; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2015-01-30       Impact factor: 8.679

3.  Human marrow stromal cells downsize the stem cell fraction of lung cancers by fibroblast growth factor 10.

Authors:  Masahiko Kanehira; Toshiaki Kikuchi; Arif Santoso; Naoki Tode; Taizou Hirano; Shinya Ohkouchi; Tsutomu Tamada; Hisatoshi Sugiura; Hideo Harigae; Masakazu Ichinose
Journal:  Mol Cell Biol       Date:  2014-05-27       Impact factor: 4.272

4.  Downregulation of USP32 inhibits cell proliferation, migration and invasion in human small cell lung cancer.

Authors:  Wenyu Hu; Haiyan Wei; Keming Li; Pei Li; Jiamao Lin; Rui Feng
Journal:  Cell Prolif       Date:  2017-06-09       Impact factor: 6.831

5.  Doxorubicin-loaded star-shaped copolymer PLGA-vitamin E TPGS nanoparticles for lung cancer therapy.

Authors:  Jinxie Zhang; Wei Tao; Yuhan Chen; Danfeng Chang; Teng Wang; Xudong Zhang; Lin Mei; Xiaowei Zeng; Laiqiang Huang
Journal:  J Mater Sci Mater Med       Date:  2015-03-20       Impact factor: 3.896

6.  Genetic mutation of p53 and suppression of the miR-17∼92 cluster are synthetic lethal in non-small cell lung cancer due to upregulation of vitamin D Signaling.

Authors:  Robert Borkowski; Liqin Du; Zhenze Zhao; Elizabeth McMillan; Adam Kosti; Chin-Rang Yang; Milind Suraokar; Ignacio I Wistuba; Adi F Gazdar; John D Minna; Michael A White; Alexander Pertsemlidis
Journal:  Cancer Res       Date:  2014-12-17       Impact factor: 12.701

7.  The Axin2 rs2240308 polymorphism and susceptibility to lung cancer in a Chinese population.

Authors:  Dan Liu; Ling Li; Yuguang Yang; Wentao Liu; Jin Wu
Journal:  Tumour Biol       Date:  2014-08-05

8.  Identifying specific Notch1 target proteins in lung carcinoma cells.

Authors:  Wael Abdo Hassan; Takaaki Ito
Journal:  Histol Histopathol       Date:  2020-10-23       Impact factor: 2.303

Review 9.  Surgery in 2013 and beyond.

Authors:  Rishendran Naidoo; Morgan N Windsor; Peter Goldstraw
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

10.  Evaluation of role of Notch3 signaling pathway in human lung cancer cells.

Authors:  Wael Abdo Hassan; Ryoji Yoshida; Shinji Kudoh; Yamato Motooka; Takaaki Ito
Journal:  J Cancer Res Clin Oncol       Date:  2016-02-02       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.